Kennedy Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$18.9M Buy
198,557
+5,342
+3% +$570K 0.36% 81
2026
Q2
$21.5M Buy
193,215
+127,397
+194% +$11.5M 0.38% 69
2026
Q1
$5.72M Buy
65,818
+25,931
+65% +$2.52M 0.12% 260
2025
Q4
$4.27M Buy
39,887
+312
+0.8% +$33.1K 0.09% 324
2025
Q3
$4M Sell
39,575
-17,642
-31% -$1.64M 0.09% 330
2025
Q2
$3.62M Buy
57,217
+2,287
+4% +$140K 0.09% 344
2025
Q1
$2.91M Buy
+54,930
New +$3.05M 0.07% 373
2024
Q3
– Sell
-11,154
Closed -$458K – 728
2024
Q2
$458K Buy
+11,154
New +$445K 0.01% 641

Other funds holding RYTM

Kennedy Capital Management's RYTM Position: Q3 2026 in Review

Kennedy Capital Management increased its Rhythm Pharmaceuticals (RYTM) stake by 2.8% in Q3 2026, buying an estimated $570K and bringing the position to 198,557 shares worth $18.9M. The position accounts for 0.36% of the portfolio, ranked #81.

Kennedy Capital Management first reported a position in RYTM in Q2 2024 and has held it in 8 quarters since. The position peaked at $21.5M in Q2 2026. 334 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Kennedy Capital Management held 198,557 shares of Rhythm Pharmaceuticals worth $18.9M as of Q3 2026.
  • Kennedy Capital Management bought 5,342 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $570K.
  • Rhythm Pharmaceuticals made up 0.36% of Kennedy Capital Management's portfolio in Q3 2026, its #81 holding.
  • Kennedy Capital Management first reported a position in Rhythm Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Kennedy Capital Management's Rhythm Pharmaceuticals position peaked at $21.5M in Q2 2026.
  • 334 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.